| P50 | author | In Ki Cho | Q90333413 |
| P2093 | author name string | Alvince Learnz Pongos | |
| | Anthony Wing Sang Chan | |
| | Carissa Emerson Hunter | |
| | Sarah Ye | |
| P2860 | cites work | Huntington's disease: a clinical review | Q21202876 |
| | Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease | Q24626259 |
| | Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice | Q24635187 |
| | Towards a transgenic model of Huntington's disease in a non-human primate | Q24644013 |
| | Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells | Q27324212 |
| | Efficient derivation of multipotent neural stem/progenitor cells from non-human primate embryonic stem cells | Q27335801 |
| | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 |
| | Huntington's disease | Q28365461 |
| | Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients | Q28542911 |
| | Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease | Q28729121 |
| | Engraftable neural crest stem cells derived from cynomolgus monkey embryonic stem cells. | Q53368538 |
| | Huntington disease | Q56083219 |
| | Singles engage the RNA interference pathway | Q84913461 |
| | Single-stranded siRNAs activate RNAi in animals | Q84913472 |
| | Huntington disease | Q89292912 |
| | Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery | Q89353427 |
| | Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease | Q39795092 |
| | Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. | Q41187089 |
| | Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. | Q41325951 |
| | CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease | Q41661649 |
| | Taking a break from huntingtin | Q41834318 |
| | Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate | Q42072961 |
| | CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo | Q42504823 |
| | Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease | Q42578017 |
| | Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein | Q42598739 |
| | Juvenile Huntington disease | Q43963261 |
| | Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease | Q45290871 |
| | Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease | Q45294512 |
| | Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease | Q45298203 |
| | Inhibition of Huntington synthesis by antisense oligodeoxynucleotides | Q45301678 |
| | MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease | Q45302123 |
| | Speech and language delay are early manifestations of juvenile-onset Huntington disease | Q45302788 |
| | Therapies targeting DNA and RNA in Huntington's disease | Q45304275 |
| | The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes | Q47772508 |
| | Huntington disease | Q48465200 |
| | Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. | Q48840079 |
| | Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 |
| | Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. | Q30356472 |
| | A two years longitudinal study of a transgenic Huntington disease monkey | Q30577737 |
| | Huntington disease: natural history, biomarkers and prospects for therapeutics | Q30774172 |
| | Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease | Q33533774 |
| | Gametic but not somatic instability of CAG repeat length in Huntington's disease. | Q33596051 |
| | Developmental Whole Brain White Matter Alterations in Transgenic Huntington's Disease Monkey | Q33671108 |
| | Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. | Q33713689 |
| | microRNA-128a dysregulation in transgenic Huntington's disease monkeys | Q33786296 |
| | Cell-based therapies for Huntington's disease | Q33849242 |
| | RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model | Q33936969 |
| | Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin | Q34221351 |
| | Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat | Q34348297 |
| | Reprogramming Huntington Monkey Skin Cells into Pluripotent Stem Cells | Q34356830 |
| | A common gene expression signature in Huntington's disease patient brain regions | Q34446889 |
| | Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells | Q34469493 |
| | Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood | Q35597258 |
| | Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease | Q35711351 |
| | RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression | Q35860947 |
| | miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells | Q36133682 |
| | Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. | Q36239309 |
| | Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice | Q36389503 |
| | Multiple pathways contribute to the pathogenesis of Huntington disease | Q36686156 |
| | Refining the diagnosis of Huntington disease: the PREDICT-HD study | Q36732557 |
| | Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain | Q36787847 |
| | Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons | Q37179338 |
| | Mechanisms of neurodegeneration in Huntington's disease. | Q37202865 |
| | Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. | Q37494307 |
| | Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. | Q37536671 |
| | Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines. | Q38234003 |
| | Men and mice: Relating their ages | Q38643990 |
| | AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. | Q38644645 |
| | Regenerative medicine in Huntington's disease: Strengths and weaknesses of preclinical studies. | Q39145677 |
| | Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease | Q39368017 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 7 | |
| P577 | publication date | 2019-03-26 | |
| P1433 | published in | NPG Regenerative Medicine | Q50815323 |
| P1476 | title | Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice | |
| P478 | volume | 4 | |